![A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma]()
A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular CarcinomaThomas, Melanie B.; Garrett-Mayer, Elizabeth; Anis, Munazza; Anderton, Kate; Bentz, Tricia; Edwards, Andie; Brisendine, Alan; Weiss, Geoffrey; Siegel, Abby B.; Bendell, Johanna; Baron, Ari; Duddalwar, Vinay; El-Khoueiry, Anthony · Oncology · 2018